A 17-year-old Kenyan cancer patient receiving treatment in India has received a significant medical update, with doctors confirming that the growth in her stomach is a gastrointestinal stromal tumour, commonly known as GIST.
The confirmation gives Risper Wambui’s medical team in India a definitive diagnosis to work from, marking an important step forward in her treatment journey after Kenyans rallied to fund her travel abroad.
What GIST Diagnosis Means
In a message addressed directly to the teenager, her doctor explained that recent tests had given the medical team far greater clarity about her condition.
The diagnosis, while serious, opens the door to targeted treatment options that are specifically designed to address GIST.
Before the doctors can settle on a particular medicine, however, they are waiting on the results of a mutation test. This additional test will reveal the biological characteristics driving Risper’s tumour and point the team towards the most suitable course of treatment.
Risper Told to Keep Hope Alive
Risper’s doctor was careful to stress that the diagnosis does not mean there is nothing that can be done.
GIST, the teenager was told, has medicines developed specifically to target its cancer cells, and those options will be considered once the mutation results come through.
While waiting for the mutation test results, Risper has been given clear instructions by her medical team.
She has been advised to maintain the diet and fluid intake recommended by her doctors, take prescribed medication correctly, and alert the team should her condition change or new symptoms appear.
How Risper Raised Cash for Treatment
The teenager’s story first captured widespread public attention in Kenya after she made an emotional appeal for help.
Her plea prompted a national fundraising effort that ultimately made her trip to India possible.
She travelled with her mother and is currently receiving specialised medical attention.
For those who have followed and supported Risper throughout her ordeal, the confirmed diagnosis represents a milestone, even if the road ahead still holds uncertainty.
The mutation test results are expected to shape the next chapter of her treatment, and her medical team has made clear that options remain on the table. For now,
Risper has been asked to take the journey one step at a time.
